NJ Flexi Cap Fund
The Scheme is seeks to generate long term capital appreciation by investing in equity and equity related instruments across market capitalizations.
Growthvine rating: 2/5 — ranked #33 of 53 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹12.40 (as of 2026-10-01) |
|---|
| AUM | ₹2,697 Cr |
|---|
| Expense ratio | 1.69% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhaval Patel |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −28.39% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 91.7% of Nifty 500's upside and 97.8% of its downside.
Market cap allocation
| Large cap | 54.0% |
|---|
| Mid cap | 30.3% |
|---|
| Small cap | 15.7% |
|---|
Concentration
| Top 5 holdings | 24.4% |
|---|
| Top 10 holdings | 43.1% |
|---|
| Total holdings | 51 |
|---|
| Index overlap | 22.0% |
|---|
| Active share | 78.0% |
|---|
Top holdings
- Torrent Pharmaceuticals Ltd. — 5.6%
- Bosch Ltd — 5.3%
- Dr. Lal Pathlabs Limited — 4.6%
- Eicher Motors Ltd. — 4.5%
- ICICI Bank Ltd. — 4.4%
- Marico Limited — 4.2%
- Britannia Industries Ltd. — 4.0%
- Cipla Ltd. — 3.7%
- Sun Pharmaceutical Industries Ltd. — 3.6%
- Alkem Laboratories Limited — 3.2%
Top sectors
- Pharma & Biotech — 21.8%
- Automobile — 14.9%
- Banking & Financial — 10.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −7.1% | Q3 | #36 of 50 |
| 2025 | −2.9% | Q4 (Bottom) | #38 of 43 |
| 2024 | 13.7% | Q4 (Bottom) | #38 of 42 |